Vetoquinol - Universal Registration Document - 2021

1 PRESENTATION OF THE GROUP Vetoquinol, your trusted animal health partner Vetoquinol Universal Registration Document 2020 Financial report 7 Over two years ago, under Matthieu’s guidance, Veto- quinol launched a drive to transform the company by focusing on initiative-taking, willingness and commit- ment. This transformation is inspired by Vetoquinol’s mission to “enrich human lives through devotion to animal health and welfare” and by the values shared by all its employees working on 5 continents: trust, dare and collaborate. These values make Vetoquinol what it is today, a company with a common passion, energy and commitment. Vetoquinol over the years • Acquisition of Swiss-based Chassot group (2001). • Launch of Aurizon ® , a treatment for canine otitis (2001). • Acquisition of Evsco ® and Tomlyn ® ranges (USA) (2002). • Launch of Prilium ® (canine cardiology), Propalin ® (treatment for incontinence in female dogs) and Clavaseptin ® (antibiotic) (2002). • New R&D center in France (2003). • Opening of sales office in Shanghai, China (2004). • Acquisition of Semyung Vet (South Korea) and Vet Solutions (USA) (2006). • IPO on Paris stock exchange (2006). • Creation of Vetoquinol Unipessoal Lda (Portugal) (2007). • Acquisition of Ascor Chimici (Italy) and Viavet (Scandinavia) (2008). • Creation of a development unit in Canada (2008). • Launch of Vetprofen ® (anti- inflammatory drug) and Rubénal ® (nephrology) (2008). • Acquisition of the animal health division of Wockhardt Ltd, India (2009). • Registration of Marbocyl ® in Japan (2010). • Development of the Acacia project, a new extension for developing and manufacturing innovative tablets at the Group headquarters (2010). • Launch of Kefloril ® and Ceftiocyl ® , two new antibiotics for food-producing animals (2010). • In 2010, Matthieu was appointed CEO and Étienne Frechin became Chairman of the Board of Directors. Étienne Frechin joined Vetoquinol. 1962 Relocation to Magny-Vernois. 1962 • Establishment of a foothold in Brazil with the acquisition of Farmagricola SA, a company located in the State of Sao Paulo. • European launch of Cimalgex ® , a new treatment for pain and inflammation in dogs. • European launch of Forcyl ® , a new single-injection anti- infective based on marbofloxacin. 2011 • Launch of Flevox ® , a parasiticide for dogs and cats. • Acquisition of Orsco, a veterinary drug manufacturer based near Lyon, France, which markets Zylkene ® . • New indication obtained for Forcyl ® for the treatment of dairy cows. • New marketing authorization (MA) for Forcyl ® Swine, a patented innovation developed by Vetoquinol. 2012 • Vetoquinol’s 80 th anniversary celebrated by all Group subsidiaries. • Simultaneous launches of Flexadin Plus and Flexadin Advanced, non-medicinal products designed to support joint health and function in dogs and cats, in Europe and USA. • US launch of Zylkene ® , an innovative patented product designed to help dogs and cats cope with unfamiliar situations. 2013 Creation of the Group’s first overseas subsidiary, Vetam in the Netherlands. 1977 Establishment of R&D center and export department. 1980 Creation of Galvet Ltd (Ireland). 1984 • Launch of Tolfedine ® anti- inflammatory drug. • Acquisition of Psyphac (Belgium). 1987 • Acquisition of Univet (UK), Antibioticos Pharma Vet (Spain), Austin, Dispar, Webster (Canada), Immunovet (USA) and MECA (Germany). • Creation of Vetoquinol North America and Vetoquinol Mexico. • Launch of Marbocyl ® anti- infective (1995). 1990-2000 2001-2010 Launch of “Vetoquinol” antiseptic by Joseph Frechin, a pharmacist in Lure. 1933